Glycosaminoglycan degradation (Homo sapiens)

From WikiPathways

Revision as of 07:07, 2 May 2020 by Egonw (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search
GlcAbetaChondroitin sulfate biosynthesisHyaluronanChondroitin sulfate(GlcA)1 (GlcNAc)1 (S)1(GlcA)1 (GlcNAc)2Dermatan sulfate(GalNAc)1 (GlcA)1 (S)1GUSBHEXAGUSBHPSEKeratan sulfateGLB1HYAL1ARSBGNS(GalNAc)2 (GlcA)1 (LIdoA)1 (S)3(GlcA)1 (GlcNAc)1HGSNATHYAL4hyaluronan(GalNAc)2 (GlcA)1 (LIdoA)1 (S)2(GlcA)2 (GlcNAc)2Heparan sulfateGALNSGeneProductGeneProduct(GalNAc)2 (GlcA)1 (S)1(GalNAc)2 (GlcA)1 (S)2SGSHGUSB(GlcA)2 (GlcN)1 (GlcNAc)1 (LIdoA)1 (S)3GALNSHPSE2GNS(GlcA)2 (GlcNAc)1 (S)1IDUANAGLU(GlcA)2 (GlcN)1 (GlcNAc)1 (LIdoA)1 (S)4IDSGeneProductHYAL2HYAL4Chondroitin sulfateHeparan sulfate biosynthesisHYAL4(GlcA)2 (GlcN)1 (GlcNAc)1 (S)3(GlcA)2 (GlcN)1 (GlcNAc)1 (S)2(GlcA)2 (GlcNAc)2 (S)2(GlcA)2 (GlcNAc)1 (S)2(GlcA)1 (GlcNAc)1Keratan sulfate biosynthesis(Gal)2 (GlcNAc)2 (S)3(Gal)2 (GlcNAc)2 (S)2(Gal)1 (GlcNAc)2 (S)2(Gal)1 (GlcNAc)2 (S)1(Gal)1 (GlcNAc)1 (S)1IDUAIDSHEXBHEXAHEXBGlcNAcbetaGlcAbetaGlcNAcGeneProductGUSBGUSBGlcNAcbetaGlcAbetaGalNAcSSDermatan sulfateSSGalNAcbetaIdoAbetaGlcAbetaGalNAcHeparan sulfateSSSIdoAbetaGlcNalphaGlcAbetaGlcNAcalphaGlcAalphaSSKeratan sulfateSSGalbetaGalbetaGlcNAcbetaGalbetaGlcNAcalphaSARSBIDUAIDSHYAL4HYAL4GUSBARSBGNSHPSEGUSBSGSHHPSE2NAGLUNAGLUIDUAIDSGNSGALNSHEXAHEXBGNSHEXAHEXBGLB1GLB1OMIM:252920Mucopolysaccharidosis, Type IIIBOMIM:253200Mucopolysaccharidosis, Type VIOMIM:230500Gm1-Gangliosidosis, Type IOMIM:252900Mucopolysaccharidosis, Type IIIAOMIM:309900Mucopolysaccharidosis, Type IIOMIM:253200Mucopolysaccharidosis, Type VIOMIM:230500Gm1-Gangliosidosis, Type IOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:253000Mucopolysaccharidosis, Type IVAOMIM:252920Mucopolysaccharidosis, Type IIIBOMIM:607014Hurler SyndromeOMIM:253010Mucopolysaccharidosis, Type IVBOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:252940Mucopolysaccharidosis, Type IIIDOMIM:309900Mucopolysaccharidosis, Type IIOMIM:252900Mucopolysaccharidosis, Type IIIAOMIM:253010Mucopolysaccharidosis, Type IVBOMIM:607014Hurler SyndromeOMIM:252940Mucopolysaccharidosis, Type IIIDOMIM:607014Hurler SyndromeOMIM:253000Mucopolysaccharidosis, Type IVAOMIM:607014Hurler SyndromeOMIM:309900Mucopolysaccharidosis, Type IIOMIM:252940Mucopolysaccharidosis, Type IIIDOMIM:253200Mucopolysaccharidosis, Type VIOMIM:252920Mucopolysaccharidosis, Type IIIBOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:230500Gm1-Gangliosidosis, Type IOMIM:252940Mucopolysaccharidosis, Type IIIDOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:253220Mucopolysaccharidosis, Type VIIOMIM:253010Mucopolysaccharidosis, Type IVBOMIM:309900Mucopolysaccharidosis, Type IIOMIM:252940Mucopolysaccharidosis, Type IIIDOMIM:253000Mucopolysaccharidosis, Type IVA


Description

Taken from KEGG: Glycosaminoglycan degradation - Homo sapiens (human) [1].

Some genes such as NAGZ could not be found, these have been left on the diagram as unannotated GeneProducts.

Linked with a dotted arrow to the GeneProduct nodes are diseases caused by mutation in the respective gene.

Quality Tags

Ontology Terms

 

Bibliography

No bibliography


History

View all...
CompareRevisionActionTimeUserComment
110276view07:07, 2 May 2020EgonwReplaced secondary ChEBI identifiers with a primary identifiers.
109331view23:23, 13 March 2020KhanspersOntology Term : 'classic metabolic pathway' added !
109330view23:22, 13 March 2020KhanspersOntology Term : 'glycosaminoglycan degradation pathway' added !
109128view06:06, 18 February 2020RleeModified description
109127view06:04, 18 February 2020RleeModified description
109124view05:59, 18 February 2020RleeNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
(Gal)1 (GlcNAc)1 (S)1MetaboliteG01391 (KEGG Glycan)
(Gal)1 (GlcNAc)2 (S)1MetaboliteG13074 (KEGG Glycan)
(Gal)1 (GlcNAc)2 (S)2MetaboliteG13073 (KEGG Glycan)
(Gal)2 (GlcNAc)2 (S)2MetaboliteG01977 (KEGG Glycan)
(Gal)2 (GlcNAc)2 (S)3MetaboliteG01945 (KEGG Glycan)
(GalNAc)1 (GlcA)1 (S)1MetaboliteG00872 (KEGG Glycan)
(GalNAc)2 (GlcA)1 (LIdoA)1 (S)2MetaboliteG13042 (KEGG Glycan)
(GalNAc)2 (GlcA)1 (LIdoA)1 (S)3MetaboliteG13041 (KEGG Glycan)
(GalNAc)2 (GlcA)1 (S)1MetaboliteG13043 (KEGG Glycan)
(GalNAc)2 (GlcA)1 (S)2MetaboliteG12336 (KEGG Glycan)
(GlcA)1 (GlcNAc)1 (S)1MetaboliteG09660 (KEGG Glycan)
(GlcA)1 (GlcNAc)1MetaboliteG02632 (KEGG Glycan)
(GlcA)1 (GlcNAc)1MetaboliteG10008 (KEGG Glycan)
(GlcA)1 (GlcNAc)2MetaboliteG00711 (KEGG Glycan)
(GlcA)2 (GlcN)1 (GlcNAc)1 (LIdoA)1 (S)3MetaboliteG13035 (KEGG Glycan)
(GlcA)2 (GlcN)1 (GlcNAc)1 (LIdoA)1 (S)4MetaboliteG13034 (KEGG Glycan)
(GlcA)2 (GlcN)1 (GlcNAc)1 (S)2MetaboliteG13037 (KEGG Glycan)
(GlcA)2 (GlcN)1 (GlcNAc)1 (S)3MetaboliteG13036 (KEGG Glycan)
(GlcA)2 (GlcNAc)1 (S)1MetaboliteG13040 (KEGG Glycan)
(GlcA)2 (GlcNAc)1 (S)2MetaboliteG13039 (KEGG Glycan)
(GlcA)2 (GlcNAc)2 (S)2MetaboliteG13038 (KEGG Glycan)
(GlcA)2 (GlcNAc)2MetaboliteG00526 (KEGG Glycan)
ARSBGeneProductENSG00000113273 (Ensembl)
Chondroitin sulfateMetaboliteCHEBI:37397 (ChEBI)
Dermatan sulfateMetaboliteCHEBI:18376 (ChEBI)
GALNSGeneProductENSG00000141012 (Ensembl)
GLB1GeneProductENSG00000170266 (Ensembl)
GNSGeneProductENSG00000135677 (Ensembl)
GUSBGeneProductENSG00000169919 (Ensembl)
GeneProductGeneProduct
HEXAGeneProductENSG00000213614 (Ensembl)
HEXBGeneProductENSG00000049860 (Ensembl)
HGSNATGeneProductENSG00000165102 (Ensembl)
HPSE2GeneProductENSG00000172987 (Ensembl)
HPSEGeneProductENSG00000173083 (Ensembl)
HYAL1GeneProductENSG00000114378 (Ensembl)
HYAL2GeneProductENSG00000068001 (Ensembl)
HYAL4GeneProductENSG00000106302 (Ensembl)
Heparan sulfateMetaboliteCHEBI:28815 (ChEBI)
IDSGeneProductENSG00000010404 (Ensembl)
IDUAGeneProductENSG00000127415 (Ensembl)
Keratan sulfateMetaboliteCHEBI:18331 (ChEBI)
NAGLUGeneProductENSG00000108784 (Ensembl)
SGSHGeneProductENSG00000181523 (Ensembl)
hyaluronanMetaboliteCHEBI:132153 (ChEBI)

Annotated Interactions

No annotated interactions

Personal tools